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Abstract
Purpose UCN-01 (7-hydroxystaurosporine) is a multi-
targeted protein kinase inhibitor that exhibits synergistic
activity with DNA-damaging agents in preclinical studies.
We conducted a Phase I study to determine the maximum-
tolerated dose (MTD), dose-limiting toxicity (DLT),
pharmacokinetic, and pharmacodynamic effects of UCN-
01 and irinotecan in patients with resistant solid tumors.
Experimental design Patients received irinotecan
(75–125 mg/m
2 IV on days 1, 8, 15, 22) and UCN-01
(50–90 mg/m
2 IV on day 2 and 25–45 mg/m
2 on day 23
and subsequent doses) every 42 days. Blood for pharma-
cokinetics of UCN-01 and irinotecan, and blood, normal
rectal mucosa, and tumor biopsies for pharmacodynamic
studies were obtained.
Results Twenty-ﬁve patients enrolled to 5 dose levels.
The MTD was irinotecan 125 mg/m
2 on days 1, 8, 15, 22
and UCN-01 70 mg/m
2 on day 2 and 35 mg/m
2 on day 23.
DLTs included grade 3 diarrhea/dehydration and dyspnea.
UCN-01 had a prolonged half-life and a low clearance
rate. There was a signiﬁcant reduction in SN-38 Cmax and
aminopentanocarboxylic acid (APC) and SN-38 glucuro-
nide half-lives. Phosphorylated ribosomal protein S6 was
reduced in blood, normal rectal mucosa, and tumor biop-
sies at 24 h post-UCN-01. Two partial responses were
observed in women with ER, PgR, and HER2-negative
breast cancers (TBNC). Both tumors were defective for
p53. Twelve patients had stable disease (mean duration
18 weeks, range 7–30 weeks).
Conclusion UCN-01 and irinotecan demonstrated accept-
able toxicity and target inhibition. Anti-tumor activity was
observed and a study of this combination in women with
TNBC is underway.
Preliminary results of this study were published in abstract form in J
Clin Oncol 2004;22:702s and Clin Cancer Res 2005;11:8,985s and
presented at the AACR-NCI-EORTC Molecular Targets and
Therapeutics 2005.
M. A. Arquette: Is deceased.
H. L. McLeod and H. Piwnica-Worms contributed equally to this
work.
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Introduction
Originally isolated as a protein kinase C inhibitor, UCN-01
has been shown to inhibit several protein kinases, including
Chk1, PDK1, and the cell cycle regulatory kinases, Cdk2,
Cdk4 and Cdk6 [7, 18, 46, 59–62]. As a single agent,
UCN-01 is capable of inducing cell cycle arrest at the
G1/S-border [3–6, 26, 39, 51, 66, 67] and has anti-tumor
effects in several NCI human tumor cell lines and xeno-
graft models [1, 3, 9, 27, 40, 49, 50]. When combined with
DNA-damaging agents, UCN-01 is capable of abrogating
S- and G2-checkpoints [6, 7, 13, 35, 67]. This is thought to
be due to UCN-01’s ability to inhibit the Chk1 protein
kinase, critical to the regulation of the S- and G2-check-
points in response to DNA damage in cells lacking a G1
checkpoint due to TP53 mutations [25]. With S- and
G2-checkpointabrogationby Chk1inhibition, p53-deﬁcient
cancer cells fail to arrest and undergo mitotic catastrophe
and eventually apoptosis [6, 7, 18, 28, 36, 67, 68]. Inhi-
bition of PDK1 may also be an important contributor to the
anti-tumor activity of UCN-01 [46]. Breast cancer cell lines
exposed to PDK1 inhibitors undergo cell death and exhibit
reduced proliferation rates presumably through opposition
of the PI3 K/AKT pathway [11, 31]. As a potent inhibitor
of both Chk1 and PDK1, UCN-01 has the potential to
target two important cellular processes that are frequently
deregulated in cancer cells.
InPhaseIclinicaltrials,asasingleagent,UCN-01hasbeen
evaluated using a 72 and 3 h infusion schedule [12, 47, 48].
Due to pharmacokinetic data demonstrating that UCN-01
binds tightly to a-1-acid glycoprotein (AAG) resulting in a
long half-life of several weeks, UCN-01 dosing was reduced
byhalfaftertheﬁrstcycleinbothschedules.Thislongplasma
half-life inhumansraisedthequestionastowhether UCN-01
was actually bioavailable to tissue at the concentrations
required for S/G2-checkpoint abrogation. In addition,
UCN-01 was observed to have unusual DLTs including
hyperglycemia with lactic acidosis, pulmonary toxicity
(hypoxemia), nausea, vomiting and hypotension. Phase I
studiesofUCN-01incombinationwithcarboplatin,cisplatin,
cytarabine,5-ﬂuorouracil,irinotecan,andtopotecanhavealso
been performed, and similar pharmacokinetics of UCN-01
and DLTs were observed [14, 19, 22, 30, 34, 41, 45].
WehypothesizedthatUCN-01andirinotecanwouldbean
effective regimen in a broad range of refractory malignan-
cies. Irinotecan (CPT-11, Camptosar
), a semisynthetic
analog of camptothecin, serves as a topoisomerase poison
covalently binding with topoisomerase I in a cleavable
complex with a single strand break in the DNA. In the
presence of ongoing DNA replication, the drug-stabilized
cleavable complex is converted into a double-strand break
leading to severe DNA damage and eventual apoptosis. This
anticancer agent has activity in several solid tumor malig-
nancies[54].Furthermore,synergismbetweencamptothecin
or SN-38, the active metabolite of irinotecan, and UCN-01
hasbeenshowninmultiplepreclinicalstudies[23,24,36,52,
65].WeenvisionedthatUCN-01 wouldbothinhibitChk1to
abrogate checkpoint responses induced by irinotecan and
inhibit PDK1 to induce apoptosis. In this Phase I study, we
set out to determine the MTD, assess the safety and toxicity,
andconductpharmacokineticandpharmacodynamicstudies
tofurtherunderstandthemolecularbasisofUCN-01activity
in combination with irinotecan.
Patients and methods
Patient eligibility
Patients at least 18 years of age were eligible for enrollment
into the study if they had a histologically conﬁrmed malig-
nant solid tumor for which standard curative treatment did
notexistorwasnolongereffective,measurableorevaluable
disease, and an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2. Laboratory criteria
included absolute neutrophil count C1,500/ll, platelet
counts C100,000/ll, serum creatinine B1.5 9 upper limit
of normal (ULN), aspartate aminotransferase and alanine
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123aminotransferase B3 9 ULN, and total bilirubin B1.5 9
ULN. Prior chemotherapy or radiotherapy must have been
completed at least 4 weeks prior to treatment. Patients with
brainmetastasis,knownsensitivitytoUCN-01oririnotecan,
insulin-dependant diabetes mellitus or uncontrolled inter-
current illness, diagnosis of Gilbert’s disease, or chronic
unconjugated hyperbilirubinemia were excluded. Initially,
all patients on this trial were required to have a
DLCO C60% and oxygen saturation C90% on room air at
rest and after a 6-min walk. However, to increase eligibility,
therequirementtoobtainaDLCOwasremoved.TheCancer
Therapy Evaluation Program (P5582), Division of Cancer
Treatment and Diagnosis, National Cancer Institute (CTEP,
NCI) and the Washington University Human Research
Protection Ofﬁce approved this protocol. All patients
provided written informed consent prior to study entry.
Treatment plan and study design
Patients received irinotecan (Camptosar
, Pﬁzer Inc., New
York, NY) as a 90-min intravenous infusion on days 1, 8,
15, and 22 and UCN-01 (Kyowa Hakko Kogyo Co.,
Shizuoka, Japan and supplied by CTEP, NCI) as a 3-h
continuous intravenous infusion on days 2 and 23 every
42 days as proposed in the dose escalation schema in
Table 1. The ﬁrst dose of UCN-01 (day 1 of cycle 1) was
twice that used in remaining doses due to the prolonged
half-life of UCN-01.
Three to six patients were enrolled at each dose level.
Toxicities were graded in accordance with the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTC) version 2.0. Dose-limiting
toxicity (DLT) was determined by toxicity observed during
cycle 1. DLT was deﬁned as grade 4 neutropenia of any
duration, febrile neutropenia, grade 3 or 4 thrombocyto-
penia, grade 3 and 4 non-hematologic toxicity including
grade 3 diarrhea lasting more than 24 h despite optimal
supportive medications, grade 4 vomiting despite optimal
antiemetic therapy, and any toxicity causing a delay of
[14 days. Grade 3 nausea, vomiting, and hyperglycemia
were not considered a DLT. If a DLT occurred in one of
three patients, up to 3 additional patients were treated at
that dose level. If two patients at this dose level experi-
enced a DLT, enrollment would be terminated. If only one
of six patients experienced a DLT, dose escalation pro-
ceeded. The maximum-tolerated dose (MTD) was deﬁned
as one dose level lower than that with which at least two
patients experienced a DLT.
Dose modiﬁcations for irinotecan and UCN-01 included
dose delays and reductions. Treatment with irinotecan
alone or in combination with UCN-01 was delayed until
the following criteria were met: the absolute neutrophil
count(ANC) C1,500cells/lL,platelets C100,000cells/lL,
hemoglobin C10, and all other treatment-related toxici-
ties Bgrade 1. When treatment resumed, irinotecan was
reduced by 25 mg/m
2 for grade 3 and 50 mg/m
2 for grade 4
hematologic and non-hematologic toxicities. For grade 2
hematologic and non-hematologic toxicities, irinotecan
was reduced by 25 mg/m
2 in the current cycle of treatment
and returned to normal dosage in subsequent cycles, pro-
vided the above criteria were met. For grade 2 hypergly-
cemia and grade 3 and 4 hyperglycemia and nausea and
vomiting, UCN-01 was also reduced by 10 mg/m
2 for all
subsequent treatments. For irreversible grade 2 cardiopul-
monary toxicity or grade 3 or 4 cardiopulmonary or hepatic
toxicity, patients were removed from study. If irinotecan
was delayed for toxicity on day 22 and subsequently
administered on day 29, the UCN-01 was also delayed and
given on day 30. Any treatment-related toxicity requiring a
delay of [14 days in the ﬁrst cycle was considered dose
limiting. If, after the appropriate dose reductions, a treat-
ment-related toxicity required a delay of [14 days in
subsequent cycles, the patient was taken off study.
Antitumor response was evaluated by physical exami-
nation and/or imaging pre-study and every cycle.
Responses were deﬁned by Response Evaluation Criteria in
Solid Tumors (RECIST) [64].
Pharmacokinetic monitoring
Plasma samples were obtained to determine the pharma-
cokinetics of total UCN-01 and irinotecan and its metab-
olites, SN-38, SN-38 glucuronide (SN-38G), and APC.
Samples were obtained prior to UCN-01 infusion, 5 min
before the end of the infusion, 20-26 h post-UCN-01
infusion, and days 8, 15, and 22 for patients in Dose Levels
1–3. Sampling was extended for patients in Dose Levels 4
and 5 to include the additional samples: 0.5, 1.5 h, and
post-infusion at 0.5, 2, 4, 24, 48 h. Plasma samples were
analyzed using modiﬁcations to previous analytical assays
consisting of high-performance liquid chromatography
(HPLC) with ﬂuorescence detection [12, 22]. UCN-01
plasma quantitative range was 0.2–60 lg/mL.
Table 1 Dose escalation schema
Dose
level
No. of
patients
Irinotecan
(mg/m
2)
UCN-01
(mg/m
2)*
No. of
DLTs
1 3 75 50 0
2 3 75 70 0
3 6 100 70 1
48
# 125 70 1
5 5 125 90 3
* Subsequent doses of UCN-01 were half the dose of this ﬁrst dose
# Two patients did not complete the ﬁrst cycle
Cancer Chemother Pharmacol (2011) 67:1225–1237 1227
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prior to irinotecan infusion, and at 0.25, 1.5, 2.25, 3.0, 5.5,
8.5, 24 h (prior to the start of UCN-01), 27 h (prior to the
end of the UCN-01 infusion), and 48 h after the start of the
irinotecan infusion on the ﬁrst and second weekly doses of
irinotecan. Plasma samples were analyzed for irinotecan
and its metabolites using a modiﬁed HPLC technique with
ﬂuorescence detection as previously described [43].
Pre-treatment AAG was determined using a nephelo-
metric assay (Focus Diagnostics, Inc., Cypress, CA). The
normal range of AAG using this assay is 36–126 mg/dL.
Individual plasma concentrations of UCN-01, irinotecan
and metabolites were analyzed using non-compartmental
methods as implemented in the computer software program
WinNonlin version 5.0 (Pharsight, Inc., Mountain View,
CA) [17, 22]. ANOVA was used to determine the associ-
ation among patient demographics and UCN-01 and iri-
notecan exposure and worst grade of toxicity during
course 1. The method of Tukey–Kramer was used to adjust
for multiple comparisons of mean values. Statistical anal-
ysis was done using JMP Statistical Discovery Software
version 3.2.6 (SAS Institute, Cary, NC). The a priori level
of signiﬁcance was P\0.05.
Pharmacodynamic studies
Peripheral blood mononuclear cells (PBMC) were collected
at baseline (day 1), 24 h post-irinotecan but prior to UCN-
01 (day 2), 24 h post-UCN-01 treatment (day 3) and on day
8 prior to the second irinotecan treatment during cycle 1 for
24 patients for Western blot analysis of phosphorylated
ribosomal protein S6. Samples from patient #7 were
excluded from analysis due to poor quality. The PBMC
were lysed in loading buffer (10% glycerol, 2% sodium
dodecyl sulfate, 0.0625 M Tris–HCl, pH 6.8 and 5%
b-mercaptoethanol), boiled for 10 min, sonicated for 5 min
in a water bath sonicator, re-boiled for 3 min, and pelleted
at 16,000g for 5 min. Supernatants were assayed for protein
concentration, and 60 lg of total cellular protein was run on
Criterion gels (Bio-Rad Laboratories, Hercules, CA) after
adding bromophenol blue. Proteins were transferred to
PVDF and probed with phospho-S6 ribosomal protein
Ser240/244, S6 ribosomal protein (Cell Signaling Tech-
nology, Inc., Danver, MA), and actin (Sigma Chemical Co.,
St. Louis, MO). Blots were developed using ECL detection
reagent (GE Healthcare, Piscataway, NJ), and proteins were
quantitated using ImageJ [2]. The ratio of phosphorylated
S6 to total S6 protein was determined for each sample.
Biopsies of normal rectal mucosa performed by colon-
oscopy were obtained at baseline and 24 h post-UCN-01
for immunohistochemistry (IHC) of phosphorylated S6 on
patients from Dose Levels 1–3. However, due to slow
accrual to this study, thought secondary to these biopsies,
this study requirement was made optional for patients on
Dose Levels 4 and 5. Skin punch biopsies (4 mm) from two
women (patients 14 and 24) from Dose Level 4 with
metastatic breast cancer to the skin of the chest wall were
also obtained at baseline and 24 h post-UCN-01 for IHC of
phosphorylated S6 (Cell Signaling Technology, Danver,
MA), Cdc2p34 Tyr15 (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA), Chk1 Ser317 and cleaved caspase 3 (Cell
Signaling Technology, Inc., Danvers, MA), phosphohi-
stone H3, and histone H2AX Ser139 (Millipore Corpora-
tion, Billerica, MA). Both rectal mucosa and tumor
biopsies were ﬁxed in formalin, processed for hematoxylin
and eosin staining, and reviewed by a pathologist to con-
ﬁrm cellularity prior to IHC studies. Immunodetection was
performed using the Histostain-Plus Kits (Zymed Labora-
tories Inc, South San Francisco, CA). Blocking solution
and rabbit IgG were used as negative controls for the IHC.
The intensity of staining was graded from 0 to 3, zero being
no staining, (1) light, (2) intermediate, and (3) strong
staining. The distribution of staining (percentage of tumor
cells staining positive) was also assessed.
Tumor genomic DNA was isolated from three patients
(patients 14, 22, and 24) with metastatic breast cancer (two
from the baseline chest wall tumor biopsies and one from
the archival primary breast tumor surgical specimen) and
analyzed for TP53 mutation by direct nucleotide sequenc-
ing of polymerase chain products of exons 4–9. Due to the
quality of tissue samples, TP53 sequencing was successful
in only two (from patients 14 and 24) of the three speci-
mens. IHC of p53 (Santa Cruz Biotechnology, Inc, Santa
Cruz, CA) (1:200 dilution, overnight) was performed on
the third patient sample (patient 22), using the same
detection methodology described previously.
Tumor genomic DNA from the chest wall breast tumor
biopsy of two patients was analyzed for TP53 mutations by
direct nucleotide sequencing of polymerase chain products
of each of the exons 4–9.
For Western blot analyses of pS6/S6 in PBMC, a natural
log transformation of the pS6/S6 ratio was required for a
normal distribution necessary for the application of stan-
dard parametric tests. After log transformation, a paired
t test and one-way ANOVA were used to assess the dif-
ferences among different time points (days 1, 2, 3, 8).
Homogeneity of pS6/S6 ratio variance was assessed by
Levene’s test, and the variances were found to be equal.
Results
Patient characteristics
Between January 2002 and January 2007, 25 patients with
advanced resistant solid tumor malignancies were enrolled.
1228 Cancer Chemother Pharmacol (2011) 67:1225–1237
123Patient characteristics are summarized in Table 2. The
majority of patients had breast or colorectal cancer and had
multiple prior therapies.
Treatment administration
Twenty-three of the 25 patients completed at least one
cycle of treatment (range 1–5) for a total of 52 cycles. Two
patients at Dose Level 4 did not complete the ﬁrst cycle of
therapy due to progressive disease. As per study design,
three patients were treated at each dose level (Table 1).
Patients at Dose Levels 1 and 2 were treated without a
DLT. At Dose Level 3, one of the ﬁrst three patients had
grade 3 dyspnea, which was a DLT. Three additional
patients were added with no further DLTs. At Dose Level
4, four patients (one patient did not complete a full cycle
due to progressive disease) were treated without DLT. At
Dose Level 5, one of the ﬁrst 3 patients had a DLT con-
sisting of grade 3 diarrhea with accompanied dehydration
and grade 3 hypokalemia and neutropenia. Thus, two
additional patients were added. One of these patients
developed a DLT consisting of grade 3 diarrhea. The other
patient developed grade 3 hypophosphatemia and grade 3
nausea and vomiting. As a result, no further patients were
treated at Dose Level 5 and 4 additional patients were
added to Dose Level 4. Of the ﬁrst 3 additional patients,
one patient received one weekly treatment with irinotecan
and UCN-01 and developed grade 4 vomiting and grade 3
dehydration (a DLT). This patient was taken off study due
to progressive disease, and a fourth patient was treated
without complication. Therefore, the MTD was considered
Dose Level 4 (irinotecan 125 mg/m
2 on days 1, 8, 15, and
22 and UCN-01 70 mg/m
2 on day 2 and 35 mg/m
2 on day
23 and all subsequent doses on a 42-day cycle).
Toxicity
The most common hematologic toxicity was neutropenia
with 48% of patients exhibiting grade 2 or 3 neutropenia
during the ﬁrst cycle (Table 3). One patient at Dose Level
3 had a 13-day delay due to grade 3 neutropenia. One
patient at Dose Level 1, two patients each at Dose Levels 3
and 4, and 3 patients at Dose Level 5 had a 1-week delay
due to grade 2 neutropenia. The most common non-
hematologic toxicities were nausea/vomiting (60%), fati-
gue/malaise (48%), diarrhea (48%), and hyperglycemia
(44%). Other toxicities included anorexia, dehydration
(associated with nausea/vomiting or diarrhea), dyspnea,
hypotension, abdominal pain or cramping, stomatitis
(Table 3). UCN-01 Cmax was related to worst grade of
hypotension during course 1 (P = 0.04), but there was no
clear correlation of increased exposure to increased grade
of toxicity. Irinotecan, and not the metabolite day 1 AUC,
was related to the worst grade of diarrhea (P = 0.02) with
increasing irinotecan exposure resulting in increased tox-
icity. Other measures of drug exposure for either irinotecan
or UCN-01 were not correlated with other toxicities.
Pharmacokinetics
Blood sampling for pharmacokinetics was obtained on 25
patients for UCN-01 and on 23 patients for irinotecan.
A summary of the UCN-01 pharmacokinetic variables is
presented in Table 4. At the MTD (Dose Level 4), the
recommended dose level for this current study, the mean
values for peak plasma concentration (Cmax), and area
under the plasma concentration–time curve (AUC[0–?])
were 15.4 lg/mL and 4,793 lg*h/mL, and values for these
exposure variables varied 2.1- and 2.7-fold, respectively.
These parameters are comparable to those reported from
the Phase 1 study of 3-h infusion of UCN-01 as a single
agent [12, 47]. Despite a statistically signiﬁcant decrease in
Cmax (P = 0.01) with increasing dose level, there was no
difference in the AUC[0–?] (P = 0.29) or systemic clear-
ance (P = 0.10) as a function of dose level.
The relationships between pre-treatment AAG and UCN-01
pharmacokinetic variables were assessed to elucidate
clinical variables that may be related to UCN-01 exposure.
Pre-treatment AAG was determined in all patients with
median level of 119 mg/dL (range 35–287 mg/dL). There is
a signiﬁcant relationship between total UCN-01 clearance
and AAG concentration and with increasing AAG
Table 2 Patient characteristics
Characteristics No. patients
(n = 25)
Age (y)
Mean (range) 54 (19–75)
Sex
Female: male 15:10
ECOG performance status
01 3
18
24
Tumor types
Breast 10
Colorectal 6
Unknown primary 2
Other (anus, esophagus, head & neck,
osteosarcoma, ovary, pancreas, prostate)
7
Prior therapy
Chemotherapy 25
Mean no. regimens (range) 3.5 (1–6)
Radiotherapy 16
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2 =
0.362; P = 0.004).
Asummaryoftheirinotecanpharmacokineticvariablesis
presented in Table 4. When using a paired t-test to compare
AUC, Cmax, and T1/2 on both day 1 and day 8, there was a
signiﬁcantincreaseinAPCCmax(P = 0.05)andreductionin
APC T1/2 (P = 0.02), SN-38 Cmax (P = 0.006), and SN-38
glucuronide T1/2 (P = 0.04). This did not translate into
signiﬁcant alterations in APC, SN38, or SN-38 glucuronide
AUC or metabolite/irinotecan AUC ratio (P[0.05).
Pharmacodynamics
The avid binding of UCN-01 to serum AAG raised the
concern of the tissue bioavailability of UCN-01 and
potential target inhibition at clinically tolerable doses.
Since a key downstream target of PDK1 is p70S6 K, which
phosphorylates S6 [37, 63], we hypothesized that if UCN-
01 inhibited PDK1, we would observe reduced pS6.
Western blot analyses for S6 and pS6 were performed on
the peripheral blood mononuclear cells (PBMC) isolated
from patient blood (Fig. 1). Representative Western blots
of pS6 pre- and post-therapy are shown for three patients
(one in Dose Level 4 and 2 in Dose Level 5) and in each
case, treatment with UCN-01 (day 3) resulted in a reduction
in pS6 but did not alter total levels of S6 (Fig. 1a). Results
were analyzed for 23 patient samples (Fig. 1b-d). Impor-
tantly, a statistically signiﬁcant decrease in pS6 was
observed on day 3 (24 h following UCN-01 treatment)
compared with pre-treatment samples (P\0.0001).
Irinotecan treatment alone did not signiﬁcantly alter pS6
levels (P = 0.29). Interestingly, levels of pS6 rose in
PBMC by day 8, six days after the ﬁrst dose of UCN-01,
and levels of pS6 between days 1 and 8 were no longer
signiﬁcantly different (P = 0.015). Taken together, these
results indicate that UCN-01 is bioavailable for at least
24 h after the ﬁrst dose but may not be available at thera-
peutic levels by day 8.
Table 3 Incidence of toxicities in cycle 1
Adverse event Dose level
Grade of adverse
event
1( n = 3) 2 (n = 3) 3 (n = 6) 4 (n = 8) 5 (n = 5)
123412 3 4 1 2 34 1 2 341 2 3 4
Blood/bone marrow
Hemoglobin 1 1 1 1 4 1* 3 3 1 3 2
Neutrophils/granulocytes 1 1 1 1 2 1* 2 1 3 1
#
Platelets 1
Constitutional symptoms
Fatigue/malaise 1 1 1 1 2 1 1* 2 2
Cardiovascular
Hypotension 12
Gastrointestinal
Anorexia 1 1 1 1 1 1
Dehydration 1** 1
#
Diarrhea 2 1 1 2 2 1 1 2
d#
Nausea/vomiting 1 2 1 1 1 2 1 1** 2 1 2
??
Stomatitis 1 2
Metabolic/laboratory
Hyperglycemia 2 1 1 1 2 1 3
Hypocalcemia 21 2
Hypokalemia 1 2 1
#
Hypophosphatemia 1 1 1
??
Pain 1 3 1 1 1 1 1
Pulmonary
Dyspnea 1 1* 1
* Dose Level 3: One patient had grade 3 dyspnea (DLT) with grade 3 fatigue, anemia and neutropenia
** Dose Level 4: One patient had grade 3 dehydration (DLT) and grade 4 vomiting
Dose Level 5:
d One patient had grade 3 diarrhea (DLT),
# one patient had grade 3 diarrhea (DLT) with grade 3 dehydration, hypokalemia, and
neutropenia, and
?? one patient had grade 3 hypophosphatemia (DLT) and grade 3 nausea/vomiting
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123Immunohistochemistry (IHC) of phosphorylated S6 was
performed on paired rectal biopsy samples (baseline and
24 h post-UCN-01) from 10 patients in Dose Levels 1–3.
In most cases, the results were not interpretable since
sections from paired specimens obtained pre- and post-
therapy were often in different orientation in relationship to
the intestinal crypts. However, in well-oriented crypts with
visible lumens, cytoplasmic pS6 staining was reduced
throughout the crypt post-therapy (data not shown). The
limited data on pS6 in rectal mucosa support that UCN-01
may be bioavailable in tissue even at the dose levels below
that of the MTD.
Serial tumor biopsies were obtained at baseline and 24 h
post-UCN-01 (48 h after irinotecan treatment) from chest
wall metastasis in two patients with metastatic breast
cancer treated in Dose Level 4. One of these two patients
had TNBC and experienced a partial response to therapy
for 18 weeks, while the other patient had estrogen and
progesterone receptor positive and HER2-negative disease
that progressed after one cycle of therapy. As seen in
Fig. 2, there was a signiﬁcant reduction in pS6 staining in
both tumor specimens post-treatment (a–d), and cH2AX
staining revealed signiﬁcantly more DNA double-strand
breaks in both tumor samples following the combination
treatment (e–h). These results demonstrate that both
irinotecan and UCN-01 were bioavailable in the tumor.
Interestingly, two patients with TNBC responded to ther-
apy and both of their tumors were found to have defective
p53. Sequencing revealed a missense mutation of CGA[
TGA:R306X in one tumor sample (Fig. 2i) and IHC
demonstrated nuclear accumulation of p53 in the second
tumor sample (Fig. 2j). One patient with ER? breast
cancer progressed after one cycle of therapy, and her tumor
was wild type for TP53 (data not shown). These results are
consistent with the preclinical ﬁndings that UCN-01 works
synergistically with DNA-damaging agents in TP53
mutated tumors [3–6, 26, 39, 51, 66, 67]. Immunohisto-
chemical analyses of cleaved caspase 3 and phosphorylated
Cdc2, Chk1, and histone H3 were performed but the
staining was variable and inconclusive.
Efﬁcacy
All patients, including the 10 patients with resistant,
recurrent breast cancer, were evaluated for response
(Supplemental Table 1). Two partial responses (8%) last-
ing 13 and 18 weeks were observed in women with triple-
negative breast cancer (TNBC, estrogen and progesterone
receptor negative and HER-2 negative) with chest wall
and lymph node recurrences previously treated with an
anthracycline, taxane, and capecitabine. Figure 2k, l reveal
pre- and post-study photos, respectively, of patient 22,
demonstrating resolution of the chest wall lesion after 2
cycles of study treatment. Twelve patients with colorectal
(5), breast (4 including 2 with TNBC), pancreatic (1), and
prostate (1) cancers and adenocarcinoma of unknown
Fig. 1 Signiﬁcant decrease in pS6 levels in PBMC following UCN-
01 treatment. PBMC were collected at baseline (day 1), 24 h post-
irinotecan but prior to UCN-01 (day 2), 24 h post-UCN-01 treatment
(day 3) and on day 8 prior to the second irinotecan treatment during
cycle 1. PBMC were lysed and analyzed by Western blotting with
antibodies speciﬁc for S6 ribosomal protein, phosphorylated S6
ribosomal protein (pS6), and actin as a loading control. Representa-
tive Western blots of PBMC from three patients are shown (a). The
arrow indicates total S6 used for normalization. The ratio of
phosphorylated S6 to total S6 protein was plotted for each sample
at each time point (b). A natural log transformation of the pS6/S6
ratio was required for a normal distribution for the application of
standard parametric tests. After log transformation, a paired t-test
(c) and one-way ANOVA (d) were used to assess the differences
among different time points (days 1, 2, 3, 8). Homogeneity of pS6/S6
ratio variance was assessed by Leveve’s test, and the variances were
found to be equal. A P-value of\0.05 is considered signiﬁcant and
is indicated by **. DF degrees of freedom, N number of samples,
CI conﬁdence interval
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123origin (1) experienced stable disease with the mean dura-
tion of 18 weeks (range 7–30 weeks). Eleven patients
including 4 with breast cancer (1 with TNBC) had pro-
gressive disease (PD).
Discussion
In this Phase 1 trial of UCN-01 and irinotecan in patients
with resistant solid tumor malignancies, we determined
the MTD and toxicity proﬁle and examined the pharma-
cokinetic parameters and target speciﬁcity of UCN-01 in
vivo. The MTD was deﬁned as Dose Level 4 (irinotecan
125 mg/m
2 on days 1, 8, 15, and 22 and UCN-01 70 mg/m
2
on day 2 and 35 mg/m
2 on day 23 of a 42-day cycle). The
total dose of irinotecan at this MTD was greater than the
dose given at the MTD in another Phase 1 study with this
combination [22]. In that study, irinotecan 60 mg/m
2 on
days 1 and 8 and UCN-01 70 mg/m
2 on day 1 and 35 mg/m
2
on day 22 of a 21-day cycle was administered. In a 6-week
time period at the MTD, patients would have received a
total of irinotecan 500 mg/m
2 in the 42-day cycle and
UCN-01 240 mg/m
2 in two 21-day cycles. While in our
study, two patients were delayed 1 week and subsequently,
dose reduced, these patients received a minimum of iri-
notecan 450 mg/m
2. In the study by Jimeno et al. [22], the
DLTs were grade 3 hypophosphatemia, grade 4 hypergly-
cemia, and febrile neutropenia. In our study, the DLTs
were grade 3 diarrhea in two patients, one of which had
associated grade 3 dehydration, hypokalemia, and hypo-
phosphatemia and grade 3 dyspnea in one patient. Though
we observed hypophosphatemia and hyperglycemia, they
were not DLTs.
The most common hematologic toxicity was neutrope-
nia with 3 patients experiencing grade 3 neutropenia
requiring a treatment delay of a least 1 week accompanied
with a dose reduction. The most common non-hematologic
toxicities included nausea, vomiting, and diarrhea often
associated with dehydration, which were not unexpected.
Diarrhea was the dose-limiting toxicity at Dose Level 5.
Fig. 2 UCN-01 decreases pS6 in tumor samples and causes a
dramatic response of chest wall lesions to therapy. IHC analysis of
pS6 on tumor specimens collected at baseline (a) and 24 h post-UCN-
01 therapy (b) from Patient 14, whose tumor carried a somatic
mutation in TP53 resulting in a change from CGA (Arginine) to TGA
(stop codon) at amino acid 306 (i). Patient 14 had TNBC to the chest
wall and lymph nodes and a partial response for 18 weeks. IHC
analysis of pS6 on tumor specimens collected at baseline (c) and 24 h
post-UCN-01 therapy (d) from Patient 24, whose tumor was ER? ,
PR? , HER2- and was wild type for TP53 by sequencing. Patient
24 had chest wall and lymph nodes metastasis and disease progression
after one cycle of study therapy. Representative ﬁelds are shown for
each specimen. Specimens from Patient 14 had pS6 intensity scores of
2 for both pre-treatment (a) and post-treatment (b), but the percentage
of tumor cells positive for pS6 was signiﬁcantly decreased, from 20%
pre-therapy to 1% post-therapy. Similarly, specimens from Patient 24
had intensity scores of 3 both pre-treatment (c) and post-therapy (d),
but the percentage of tumor cells positive for pS6 was signiﬁcantly
decreased, from 40% pre-therapy to 5% post-therapy. IHC analysis of
cH2AX on tumor specimens collected at baseline (e) and 24 h post-
UCN-01 therapy (f) from Patient 14 and at baseline (g) and 24 h post-
UCN-01 therapy (h) from Patient 24 demonstrated more DNA strand
double-strand breaks in both tumor samples following combination
treatment. Photographs of metastatic breast cancer to the skin from
Patient 22 taken at baseline (k) and following completion of 2 cycles
of therapy (l). This tumor exhibited nuclear accumulation of p53 by
IHC (j) indicative of mutant TP53. Patient 22 had metastatic TNBC to
the skin and lymph nodes and experienced a PR for 13 weeks
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123Other common toxicities were fatigue, anorexia, and
abdominal pain/cramping. Pulmonary toxicity, which has
been well documented in previous Phase I trials [47], was
also noted in our study. Three patients experienced grade
2–3 dyspnea. The presumed mechanism for the pulmonary
toxicity is currently unclear. According to Sausville et al.
[47], it is thought that UCN-01 may alter V/Q ratios and
possibly allow a functional right-to-left shunt to develop.
Eleven patients experienced hyperglycemia, which was
self-limiting in all but one patient. This patient, a diabetic
on oral hypoglycemic medications, experienced grade 3
hyperglycemia and was hospitalized brieﬂy for treatment
and continued on study with closer glucose monitoring.
This toxicity has been documented in other studies with
this agent [47]. The presumed mechanism for hypergly-
cemia is thought to be related to inhibition of Akt by UCN-
01 and resultant changes in glucose transport [29, 47].
There is potential for drug–drug interactions between
UCN-01andirinotecan.Theuniquepharmacologicalfeature
of UCN-01 is a high-afﬁnity binding to human AAG
[15,16,48].UCN-01appearstobeeliminatedinratsprimarily
bytheliveralthoughthemetabolicfatehasnotbeenelucidated
[32]. Irinotecan has a complex pharmacologic proﬁle with
metabolism by human carboxylesterases, cytochrome P450
enzymes, and UDP-glucuronyltransferases and elimination
by several drug-transporting proteins [55]. In addition,
irinotecan and the active metabolite SN-38 are bound to
albumin, AAG, and c-globulins [10]. Similar to results
fromotherPhaseIstudies,UCN-01exhibitedalonghalf-life
(427 h), low clearance (0.026 L/h), and marked variability
in AUC values (3-fold) [12, 22]. As previously observed,
there was a correlation between UCN-01 clearance and
AAG concentrations [58]. We also observed that UCN-01
exposure appeared to decline with increasing doses of iri-
notecan, although only Cmax reached statistical signiﬁ-
cance. This trend may be due to the saturation of protein
binding [58] or a drug interaction at the protein binding
level. Not unexpectedly, there were no correlations
between increasing UCN-01 exposure and increasing grade
of toxicity, which is consistent with previous reports
[12, 22]. As was previously observed, there were altera-
tions in the irinotecan pharmacokinetics albeit not the same
pharmacokinetic parameters [22]. The mechanism behind
this drug interaction is unknown.
Our correlative studies demonstrated decreases in pS6 in
PBMC, rectal mucosa, and tumor biopsies after UCN-01
treatment. The number of rectal mucosa and tumor biopsy
samples was very limited, and no conclusions could be
made. However, the decrease in pS6 was signiﬁcant in
PBMC, indicating that UCN-01 is bioavailable and inhibits
PDK1 at the MTD for at least 24 h after the ﬁrst dose of
UCN-01. Interestingly, this decrease in pS6 was no longer
observed in PBMC at day 8 of the treatment. Under the
treatment plan, irinotecan was administered on days 1, 8,
15 and 22 and UCN-01 was administered on days 2 and 23
of each 42-day cycle. The correlative studies indicate that
UCN-01 may no longer be bioavailable in tumors during
subsequent treatments with irinotecan (days 8, 15, and 22).
Therefore, this treatment regimen may not be optimal for
inducing checkpoint bypass in response to the DNA dam-
age induced by irinotecan.
Previous Phase I studies, either with single agent UCN-01
or in combination with other agents, have shown mini-
mal responses in patients with solid tumor malignancies.
Partial responses were seen in a patient with melanoma
[12, 48], a woman with adenocarcinoma of unknown pri-
mary with skin metastases (presumed to be TNBC primary,
personal communication with P.N. Lara) [34], and one
woman with ovarian cancer [19]. Interestingly, our study
demonstrates two partial responses in women with TNBC
and both of their tumors were defective in p53. Of the 12
patients with stable disease, four had breast cancer (2 with
TNBC). Given that the prognosis for women with TNBC is
poor due to the aggressive characteristics of their tumors
and limited treatment options [20, 53], the development of
more effective therapies is a high priority. TNBC typically
falls into the basal-like subtype when examined by DNA
microarray analysis [38]. Patients with basal-like breast
cancer have a signiﬁcantly shorter survival in comparison
with patients with luminal (ER?) subtypes [38, 56, 57].
Interestingly, a much higher rate of TP53 mutations (44%
in basal-like vs. 15% in luminal A subtype, P\0.001) [8]
and loss of PTEN (67% in ER-/PgR- vs. 23% in ER?
/PgR?, P\0.05) have been observed [11, 33, 42, 44].
Theoretically, agents such as UCN-01 that target proteins
in both pathways may prove to be particularly effective in a
dual TP53 and PTEN mutant tumor. Therefore, based on
the preliminary results obtained in our small subset of
women with TNBC, the NCI CTEP approved an extension
of our study (http://clinicaltrials.gov, NCT00031681) to
determine the efﬁcacy and tolerability of this combination
in these women after failure of anthracyclines and tax-
anes therapy. In addition, pharmacodynamic parameters
including TP53 mutational status and cell cycle, check-
point, and signaling proteins will be correlated with
response.
The cellular targets of UCN-01 include protein kinase C
isoforms, CDKs, Chk1, and PDK1. These targets likely
account for the varied toxicities observed in clinical trials.
Because of these toxicities, it is unclear whether UCN-01
will undergo further development. Nonetheless, more
selective checkpoint kinase inhibitors are in clinical trials
now. Over 33 patent applications have been ﬁled from
January 2006 through August 2008, claiming chemical
matter in which Chk1 or Chk2 were stated as targets of
inhibition [21]. Given the plethora of compounds that may
1234 Cancer Chemother Pharmacol (2011) 67:1225–1237
123be placed into clinical trials, it is imperative that ‘‘proof of
concept’’ trials be performed on this important class of
compounds.
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